Inhibikase Therapeutics Inc (IKT)

[conix]

Inhibikase Therapeutics gets FDA clearance for early-stage Parkinson's disease trial

Jul. 26, 2021 By: Aakash Babu, SA News Editor


Inhibikase Therapeutics (NASDAQ:IKT) announces that the U.S. FDA has given the company the greenlight to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's disease (PD) patients.

Shares up nearly 19% premarket.

The randomized Phase 1 study investigated the safety, tolerability and pharmacokinetics (PK) of IkT-148009 in healthy volunteers aged 45 to 70 years old.

Forty-two patients were dosed with IkT-148009 between 12.5 and 100 mg with no clinically significant adverse events reported.

PD is a progressive neurodegenerative disease, and affects about 1M persons in the United States.